Skip to main content

Table 1 Demographic, clinical and serologic characteristics of the three cohorts

From: Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis

Cohort Parameter
US-based (ABCoN)  
   Age (years) 50 (35 to 78)
   Female sex 23 (79)
   CCP2 56.6 (1.2 to 500)
   CRP (mg/l) 60 (2 to 79)
   ACR response < 20 15 (51.7)
   ACR response > 50 14 (48.3)
   Shared epitope present 16/24 (66)
   Disease duration (months) 96 (12 to 396)
Swedish  
   Age (years) 54 (32 to 77)
   Female sex 34 (79)
   CCP2 n.d.
   CRP (mg/l) 37.5 (10 to 166)
   ACR response < 20 19 (44.2)
   ACR response > 50 24 (55.8)
   Shared epitope present n.d.
   Disease duration (months) 108 (1 to 464)
Japanese  
   Age (years) 56 (24 to 76)
   Female sex 20 (95%)
   CCP2 n.d.
   Rheumatoid factor (units) 66.9 (14.9 to 1,675)
   CRP (mg/l) 55 (33 to 75)
   ACR response < 20 9/21 (29.0)
   ACR response > 70 12/21 (38.7)
   Shared epitope present n.d.
   Disease duration (months) 151 (11 to 444)
  1. Data presented as median (range) or n (%). ACR, American College of Rheumatology; CCP, cyclic citrullinated peptide; n.d., not determined.